Literature DB >> 28642329

Experimental and Computational Insight Into Human Mesenchymal Stem Cell Paracrine Signaling and Heterocellular Coupling Effects on Cardiac Contractility and Arrhythmogenicity.

Joshua Mayourian1, Timothy J Cashman1, Delaine K Ceholski1, Bryce V Johnson1, David Sachs1, Deepak A Kaji1, Susmita Sahoo1, Joshua M Hare1, Roger J Hajjar1, Eric A Sobie1, Kevin D Costa2.   

Abstract

RATIONALE: Myocardial delivery of human mesenchymal stem cells (hMSCs) is an emerging therapy for treating the failing heart. However, the relative effects of hMSC-mediated heterocellular coupling (HC) and paracrine signaling (PS) on human cardiac contractility and arrhythmogenicity remain unresolved.
OBJECTIVE: The objective is to better understand hMSC PS and HC effects on human cardiac contractility and arrhythmogenicity by integrating experimental and computational approaches. METHODS AND
RESULTS: Extending our previous hMSC-cardiomyocyte HC computational model, we incorporated experimentally calibrated hMSC PS effects on cardiomyocyte L-type calcium channel/sarcoendoplasmic reticulum calcium-ATPase activity and cardiac tissue fibrosis. Excitation-contraction simulations of hMSC PS-only and combined HC+PS effects on human cardiomyocytes were representative of human engineered cardiac tissue (hECT) contractile function measurements under matched experimental treatments. Model simulations and hECTs both demonstrated that hMSC-mediated effects were most pronounced under PS-only conditions, where developed force increased ≈4-fold compared with non-hMSC-supplemented controls during physiological 1-Hz pacing. Simulations predicted contractility of isolated healthy and ischemic adult human cardiomyocytes would be minimally sensitive to hMSC HC, driven primarily by PS. Dominance of hMSC PS was also revealed in simulations of fibrotic cardiac tissue, where hMSC PS protected from potential proarrhythmic effects of HC at various levels of engraftment. Finally, to study the nature of the hMSC paracrine effects on contractility, proteomic analysis of hECT/hMSC conditioned media predicted activation of PI3K/Akt signaling, a recognized target of both soluble and exosomal fractions of the hMSC secretome. Treating hECTs with exosome-enriched, but not exosome-depleted, fractions of the hMSC secretome recapitulated the effects observed with hMSC conditioned media on hECT-developed force and expression of calcium-handling genes (eg, SERCA2a, L-type calcium channel).
CONCLUSIONS: Collectively, this integrated experimental and computational study helps unravel relative hMSC PS and HC effects on human cardiac contractility and arrhythmogenicity, and provides novel insight into the role of exosomes in hMSC paracrine-mediated effects on contractility.
© 2017 American Heart Association, Inc.

Entities:  

Keywords:  cardiovascular disease; cell- and tissue-based therapy; computational biology; electrophysiology; excitation contraction coupling; exosomes; myocardial contraction

Mesh:

Year:  2017        PMID: 28642329      PMCID: PMC5899516          DOI: 10.1161/CIRCRESAHA.117.310796

Source DB:  PubMed          Journal:  Circ Res        ISSN: 0009-7330            Impact factor:   17.367


  48 in total

1.  Paracrine action accounts for marked protection of ischemic heart by Akt-modified mesenchymal stem cells.

Authors:  Massimiliano Gnecchi; Huamei He; Olin D Liang; Luis G Melo; Fulvio Morello; Hui Mu; Nicolas Noiseux; Lunan Zhang; Richard E Pratt; Joanne S Ingwall; Victor J Dzau
Journal:  Nat Med       Date:  2005-04       Impact factor: 53.440

2.  Bone marrow mesenchymal stem cells stimulate cardiac stem cell proliferation and differentiation.

Authors:  Konstantinos E Hatzistergos; Henry Quevedo; Behzad N Oskouei; Qinghua Hu; Gary S Feigenbaum; Irene S Margitich; Ramesh Mazhari; Andrew J Boyle; Juan P Zambrano; Jose E Rodriguez; Raul Dulce; Pradip M Pattany; David Valdes; Concepcion Revilla; Alan W Heldman; Ian McNiece; Joshua M Hare
Journal:  Circ Res       Date:  2010-07-29       Impact factor: 17.367

3.  Engraftment patterns of human adult mesenchymal stem cells expose electrotonic and paracrine proarrhythmic mechanisms in myocardial cell cultures.

Authors:  Saïd F A Askar; Arti A Ramkisoensing; Douwe E Atsma; Martin J Schalij; Antoine A F de Vries; Daniël A Pijnappels
Journal:  Circ Arrhythm Electrophysiol       Date:  2013-02-18

Review 4.  Harnessing the mesenchymal stem cell secretome for the treatment of cardiovascular disease.

Authors:  Sudhir H Ranganath; Oren Levy; Maneesha S Inamdar; Jeffrey M Karp
Journal:  Cell Stem Cell       Date:  2012-03-02       Impact factor: 24.633

5.  Improved graft mesenchymal stem cell survival in ischemic heart with a hypoxia-regulated heme oxygenase-1 vector.

Authors:  Yao Liang Tang; Yi Tang; Y Clare Zhang; Keping Qian; Leping Shen; M Ian Phillips
Journal:  J Am Coll Cardiol       Date:  2005-10-04       Impact factor: 24.094

6.  Intracoronary bone marrow cell transfer after myocardial infarction: 5-year follow-up from the randomized-controlled BOOST trial.

Authors:  Gerd P Meyer; Kai C Wollert; Joachim Lotz; Jens Pirr; Ulrike Rager; Peter Lippolt; Andreas Hahn; Stephanie Fichtner; Arnd Schaefer; Lubomir Arseniev; Arnold Ganser; Helmut Drexler
Journal:  Eur Heart J       Date:  2009-12       Impact factor: 29.983

7.  Transendocardial mesenchymal stem cells and mononuclear bone marrow cells for ischemic cardiomyopathy: the TAC-HFT randomized trial.

Authors:  Alan W Heldman; Darcy L DiFede; Joel E Fishman; Juan P Zambrano; Barry H Trachtenberg; Vasileios Karantalis; Muzammil Mushtaq; Adam R Williams; Viky Y Suncion; Ian K McNiece; Eduard Ghersin; Victor Soto; Gustavo Lopera; Roberto Miki; Howard Willens; Robert Hendel; Raul Mitrani; Pradip Pattany; Gary Feigenbaum; Behzad Oskouei; John Byrnes; Maureen H Lowery; Julio Sierra; Mariesty V Pujol; Cindy Delgado; Phillip J Gonzalez; Jose E Rodriguez; Luiza Lima Bagno; Didier Rouy; Peter Altman; Cheryl Wong Po Foo; Jose da Silva; Erica Anderson; Richard Schwarz; Adam Mendizabal; Joshua M Hare
Journal:  JAMA       Date:  2014-01-01       Impact factor: 56.272

Review 8.  Mesenchymal stem cells for cardiac therapy: practical challenges and potential mechanisms.

Authors:  Timothy J Cashman; Valerie Gouon-Evans; Kevin D Costa
Journal:  Stem Cell Rev Rep       Date:  2013-06       Impact factor: 5.739

9.  Experimentally calibrated population of models predicts and explains intersubject variability in cardiac cellular electrophysiology.

Authors:  Oliver J Britton; Alfonso Bueno-Orovio; Karel Van Ammel; Hua Rong Lu; Rob Towart; David J Gallacher; Blanca Rodriguez
Journal:  Proc Natl Acad Sci U S A       Date:  2013-05-20       Impact factor: 11.205

10.  Human engineered heart tissue as a versatile tool in basic research and preclinical toxicology.

Authors:  Sebastian Schaaf; Aya Shibamiya; Marco Mewe; Alexandra Eder; Andrea Stöhr; Marc N Hirt; Thomas Rau; Wolfram-Hubertus Zimmermann; Lenard Conradi; Thomas Eschenhagen; Arne Hansen
Journal:  PLoS One       Date:  2011-10-20       Impact factor: 3.240

View more
  28 in total

Review 1.  Cardiac ischemia-insights from computational models.

Authors:  Axel Loewe; Eike Moritz Wülfers; Gunnar Seemann
Journal:  Herzschrittmacherther Elektrophysiol       Date:  2018-01-05

Review 2.  Physiologic, Pathologic, and Therapeutic Paracrine Modulation of Cardiac Excitation-Contraction Coupling.

Authors:  Joshua Mayourian; Delaine K Ceholski; David M Gonzalez; Timothy J Cashman; Susmita Sahoo; Roger J Hajjar; Kevin D Costa
Journal:  Circ Res       Date:  2018-01-05       Impact factor: 17.367

Review 3.  Mesenchymal Stem Cell-Based Therapy for Cardiovascular Disease: Progress and Challenges.

Authors:  Luiza Bagno; Konstantinos E Hatzistergos; Wayne Balkan; Joshua M Hare
Journal:  Mol Ther       Date:  2018-05-25       Impact factor: 11.454

Review 4.  Beneficial effects of exosomes secreted by cardiac-derived progenitor cells and other cell types in myocardial ischemia.

Authors:  Lucio Barile; Giuseppina Milano; Giuseppe Vassalli
Journal:  Stem Cell Investig       Date:  2017-11-18

5.  Exosomal microRNA-21-5p Mediates Mesenchymal Stem Cell Paracrine Effects on Human Cardiac Tissue Contractility.

Authors:  Joshua Mayourian; Delaine K Ceholski; Przemek A Gorski; Prabhu Mathiyalagan; Jack F Murphy; Sophia I Salazar; Francesca Stillitano; Joshua M Hare; Susmita Sahoo; Roger J Hajjar; Kevin D Costa
Journal:  Circ Res       Date:  2018-02-15       Impact factor: 17.367

Review 6.  Extracellular Vesicles and the Application of System Biology and Computational Modeling in Cardiac Repair.

Authors:  Venkata Naga Srikanth Garikipati; Farnaz Shoja-Taheri; Michael E Davis; Raj Kishore
Journal:  Circ Res       Date:  2018-07-06       Impact factor: 17.367

7.  Functional and transcriptomic insights into pathogenesis of R9C phospholamban mutation using human induced pluripotent stem cell-derived cardiomyocytes.

Authors:  Delaine K Ceholski; Irene C Turnbull; Chi-Wing Kong; Simon Koplev; Joshua Mayourian; Przemek A Gorski; Francesca Stillitano; Angelos A Skodras; Mathieu Nonnenmacher; Ninette Cohen; Johan L M Björkegren; Daniel R Stroik; Razvan L Cornea; David D Thomas; Ronald A Li; Kevin D Costa; Roger J Hajjar
Journal:  J Mol Cell Cardiol       Date:  2018-05-09       Impact factor: 5.000

8.  Epigenetically modified cardiac mesenchymal stromal cells limit myocardial fibrosis and promote functional recovery in a model of chronic ischemic cardiomyopathy.

Authors:  Joseph B Moore; Xian-Liang Tang; John Zhao; Annalara G Fischer; Wen-Jian Wu; Shizuka Uchida; Anna M Gumpert; Heather Stowers; Marcin Wysoczynski; Roberto Bolli
Journal:  Basic Res Cardiol       Date:  2018-11-16       Impact factor: 17.165

9.  The Ca2+ transient as a feedback sensor controlling cardiomyocyte ionic conductances in mouse populations.

Authors:  Colin M Rees; Jun-Hai Yang; Marc Santolini; Aldons J Lusis; James N Weiss; Alain Karma
Journal:  Elife       Date:  2018-09-25       Impact factor: 8.140

Review 10.  Experimental models of cardiac physiology and pathology.

Authors:  Jae Gyun Oh; Changwon Kho; Roger J Hajjar; Kiyotake Ishikawa
Journal:  Heart Fail Rev       Date:  2019-07       Impact factor: 4.214

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.